C

CEL-SCI Corp
AMEX:CVM

Watchlist Manager
CEL-SCI Corp
AMEX:CVM
Watchlist
Price: 6.48 USD -0.77% Market Closed
Market Cap: 51.8m USD

CVM's latest stock split occurred on May 20, 2025

The company executed a 1-for-30 stock split, meaning that for every 30 shares held, investors received 1 new share.

Before the split, CVM traded at 6 per share. Afterward, the share price was about 5.11.

The adjusted shares began trading on May 20, 2025. This was CVM's 4th stock split, following the previous one in Jun 15, 2017.

Last Splits:
May 20, 2025
1-for-30
Jun 15, 2017
1-for-25
Sep 25, 2013
1-for-10
May 1, 1995
1-for-10
Pre-Split Price
6 6
Post-Split Price
5.11
Before
After
Last Splits:
May 20, 2025
1-for-30
Jun 15, 2017
1-for-25
Sep 25, 2013
1-for-10
May 1, 1995
1-for-10

CEL-SCI Corp
Stock Splits History

CVM Stock Splits Timeline
May 20, 2025
May 20, 2025
Split 1-for-30
/0.033333333333333
Pre-Split Price
6 6
Post-Split Price
5.11
Before
After
Jun 15, 2017
Jun 15, 2017
Split 1-for-25
/0.04
Pre-Split Price
60 0.08
Post-Split Price
53.7
Before
After
Sep 25, 2013
Sep 25, 2013
Split 1-for-10
/0.1
Pre-Split Price
1 500 0.2
Post-Split Price
1 372.5
Before
After
May 1, 1995
May 1, 1995
Split 1-for-10
/0.1
Pre-Split Price
32 774.7845 0.4375
Post-Split Price
31 838.3621
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.74 45.74 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
58.49 58.49 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

CEL-SCI Corp
Glance View

Market Cap
51.8m USD
Industry
Biotechnology

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on activating the immune system to fight cancer and infectious diseases. The firm is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The firm is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.

CVM Intrinsic Value
Not Available
Back to Top